Celcuity (NASDAQ:CELC - Get Free Report) had its target price dropped by Stifel Nicolaus from $40.00 to $39.00 in a report issued on Thursday, Benzinga reports. The firm currently has a "buy" rating on the stock. Stifel Nicolaus' price objective points to a potential upside of 138.82% from the company's current price.
Other equities research analysts have also recently issued reports about the company. SVB Leerink began coverage on Celcuity in a report on Monday, July 22nd. They set an "outperform" rating and a $29.00 target price for the company. Craig Hallum restated a "buy" rating and set a $27.00 target price (up from $25.00) on shares of Celcuity in a report on Thursday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a report on Thursday, May 16th. Needham & Company LLC dropped their price objective on Celcuity from $24.00 to $23.00 and set a "buy" rating for the company in a report on Friday, May 31st. Finally, Leerink Partnrs upgraded Celcuity to a "strong-buy" rating in a report on Monday, July 22nd. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $29.00.
Get Our Latest Report on CELC
Celcuity Trading Down 2.9 %
Shares of CELC stock opened at $16.33 on Thursday. The stock has a market capitalization of $573.20 million, a PE ratio of -5.87 and a beta of 0.81. Celcuity has a 1-year low of $8.39 and a 1-year high of $22.19. The business has a 50-day moving average of $16.63 and a 200 day moving average of $16.82. The company has a debt-to-equity ratio of 0.28, a current ratio of 11.23 and a quick ratio of 11.23.
Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Wednesday, May 15th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.07. As a group, sell-side analysts anticipate that Celcuity will post -2.86 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in CELC. Quest Partners LLC increased its position in Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock valued at $95,000 after buying an additional 1,379 shares in the last quarter. BNP Paribas Financial Markets increased its position in Celcuity by 78.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company's stock valued at $193,000 after buying an additional 3,930 shares in the last quarter. Pale Fire Capital SE increased its position in Celcuity by 38.4% during the 4th quarter. Pale Fire Capital SE now owns 14,409 shares of the company's stock valued at $210,000 after buying an additional 4,000 shares in the last quarter. Commonwealth Equity Services LLC increased its position in Celcuity by 9.9% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company's stock valued at $272,000 after buying an additional 1,500 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company's stock valued at $361,000 after buying an additional 1,600 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company's stock.
Celcuity Company Profile
(Get Free Report)
Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Featured Articles
- Five stocks we like better than Celcuity
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Unlocking Growth: Why Arcos Dorados Belongs in Your Portfolio
- Pros And Cons Of Monthly Dividend Stocks
- Forget Robotaxis: Electric Air Taxis are the Next Big Investment
- How to Most Effectively Use the MarketBeat Earnings Screener
- Crocs Stock Slips After Earnings Beat: Will It Bounce Back?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ California's big mistake (From Stansberry Research) (Ad)
Should you invest $1,000 in Celcuity right now?
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
10 Best Stocks to Own in 2024
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
